Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sanofi India Limited (SANOFI.NS)
INR3,341.00
-58.20 (-1.71%)
IN NSE Healthcare Medical - Pharmaceuticals
Address
Sanofi House CTS No. 117-B Mumbai
Mumbai, MH, IN
Mumbai, MH, IN
CEO
Deepak Arora
Website
sanofiindialtd.com
IPO
1994-11-03
ISIN INE058A01010
Also trades on
Bombay Stock Exchange · SANOFI.BO (INR)
National Stock Exchange of India · SANOFI.NS (INR)
Description
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR3,341.00
-58.20 (-1.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31.9K
Beta
0.17
Float Shares
9.07M
Free Float %
39.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.78% | -2.16% | -4.01% | -10.86% | -26.43% | -23.64% | -49.23% | -21.44% | -31.16% | +28.67% | +241.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,341.00
DCF (Unlevered)
5,252.13
+57.2%
DCF (Levered)
8,644.26
+158.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
11.39
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-8.7% Q1'26: +0.3% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+4.1% Q1'26: +8.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+22.3% Q1'26: +29.3% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+24.3% ★ Q1'26: +29.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+66.6% ★ Q1'26: +83.6% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.04× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.51B
est.
|
6.50B
est.
|
6.60B
est.
|
7.35B
est: 6.96B (+5.6%)
|
8.08B
est: 8.14B (-0.7%)
|
8.84B
est: 8.92B (-0.9%)
|
8.74B
est: 9.19B (-4.9%)
|
9.83B
est: 9.42B (+4.3%)
|
9.74B
est: 10.20B (-4.5%)
|
10.85B
est: 10.85B (+0.0%)
|
12.30B
est: 12.87B (-4.5%)
|
15.73B
est: 15.56B (+1.1%)
|
18.09B
est: 17.68B (+2.3%)
|
19.77B
est: 20.05B (-1.4%)
|
21.93B
est: 21.43B (+2.3%)
|
23.67B
est: 23.78B (-0.5%)
|
24.64B
est: 24.71B (-0.3%)
|
27.71B
est: 27.46B (+0.9%)
|
30.71B
est: 29.55B (+3.9%)
|
29.02B
est: 28.78B (+0.8%)
|
29.57B
est: 29.31B (+0.9%)
|
27.70B
est: 27.80B (-0.4%)
|
19.96B
est: 27.90B (-28.5%)
|
20.13B
est: 20.39B (-1.3%)
|
18.37B
est: 19.07B (-3.7%)
|
19.50B
19.40B – 19.59B
+2.2% YoY
|
20.68B
20.40B – 20.96B
+6.1% YoY
|
21.47B
21.27B – 21.68B
+3.8% YoY
|
| EBITDA |
1.36B
est.
|
1.27B
est.
|
1.07B
est.
|
2.36B
est: 1.84B (+28.3%)
|
2.51B
est: 3.01B (-16.7%)
|
2.64B
est: 2.78B (-5.1%)
|
2.37B
est: 2.76B (-14.0%)
|
2.78B
est: 2.77B (+0.4%)
|
2.59B
est: 3.39B (-23.6%)
|
2.54B
est: 3.10B (-18.2%)
|
3.15B
est: 4.31B (-26.8%)
|
3.22B
est: 4.45B (-27.6%)
|
4.16B
est: 4.21B (-1.3%)
|
3.56B
est: 5.87B (-39.4%)
|
4.60B
est: 5.69B (-19.1%)
|
5.33B
est: 7.04B (-24.3%)
|
5.36B
est: 6.95B (-22.9%)
|
6.24B
est: 7.65B (-18.5%)
|
6.66B
est: 8.51B (-21.7%)
|
7.09B
est: 8.06B (-12.0%)
|
7.54B
est: 8.65B (-12.8%)
|
6.98B
est: 8.96B (-22.1%)
|
4.85B
est: 8.96B (-45.9%)
|
4.85B
est: 9.48B (-48.8%)
|
4.84B
est: 5.23B (-7.6%)
|
5.35B
5.32B – 5.38B
+2.2% YoY
|
5.67B
5.60B – 5.75B
+6.1% YoY
|
5.89B
5.83B – 5.95B
+3.8% YoY
|
| EBIT |
1.26B
est.
|
974.86M
est.
|
825.57M
est.
|
2.26B
est: 1.49B (+51.4%)
|
2.36B
est: 2.56B (-7.8%)
|
2.50B
est: 2.27B (+10.2%)
|
2.23B
est: 2.09B (+6.8%)
|
2.60B
est: 1.53B (+70.4%)
|
2.42B
est: 1.82B (+32.8%)
|
2.37B
est: 1.39B (+70.6%)
|
2.84B
est: 1.50B (+89.3%)
|
2.32B
est: 1.76B (+32.4%)
|
3.24B
est: 2.52B (+28.3%)
|
2.59B
est: 3.57B (-27.5%)
|
3.48B
est: 2.85B (+22.1%)
|
4.16B
est: 3.80B (+9.4%)
|
4.35B
est: 4.39B (-0.8%)
|
5.23B
est: 4.81B (+8.7%)
|
5.68B
est: 5.57B (+1.9%)
|
6.34B
est: 5.17B (+22.6%)
|
6.96B
est: 5.55B (+25.4%)
|
6.66B
est: 5.75B (+15.8%)
|
4.54B
est: 5.75B (-21.1%)
|
4.54B
est: 5.13B (-11.4%)
|
4.46B
est: 4.80B (-6.9%)
|
4.90B
4.88B – 4.93B
+2.2% YoY
|
5.20B
5.13B – 5.27B
+6.1% YoY
|
5.40B
5.35B – 5.45B
+3.8% YoY
|
| Net Income |
613.41M
est.
|
785.08M
est.
|
620.45M
est.
|
1.48B
est: 1.10B (+34.6%)
|
1.45B
est: 1.82B (-20.4%)
|
1.69B
est: 1.59B (+6.4%)
|
1.44B
est: 1.74B (-17.2%)
|
1.66B
est: 1.48B (+12.5%)
|
1.57B
est: 1.80B (-12.5%)
|
1.55B
est: 1.67B (-7.4%)
|
1.91B
est: 2.74B (-30.2%)
|
1.77B
est: 2.31B (-23.6%)
|
2.65B
est: 2.01B (+32.1%)
|
2.64B
est: 2.99B (-11.9%)
|
3.22B
est: 2.91B (+10.5%)
|
3.04B
est: 3.52B (-13.6%)
|
3.26B
est: 3.20B (+1.8%)
|
3.81B
est: 3.59B (+5.9%)
|
4.14B
est: 4.06B (+2.1%)
|
4.78B
est: 4.21B (+13.4%)
|
9.44B
est: 4.52B (+108.9%)
|
6.21B
est: 4.69B (+32.4%)
|
6.03B
est: 4.69B (+28.7%)
|
4.13B
est: 4.95B (-16.6%)
|
3.27B
est: 3.82B (-14.6%)
|
3.87B
3.76B – 3.98B
+1.2% YoY
|
3.99B
3.69B – 4.28B
+3.2% YoY
|
3.97B
3.92B – 4.02B
-0.5% YoY
|
| SGA |
863.30M
est.
|
1.92B
est.
|
1.84B
est.
|
1.52B
est: 2.03B (-25.4%)
|
1.59B
est: 2.29B (-30.4%)
|
1.76B
est: 2.28B (-22.7%)
|
2.01B
est: 2.42B (-17.0%)
|
2.29B
est: 2.80B (-18.4%)
|
2.51B
est: 3.47B (-27.8%)
|
2.74B
est: 3.64B (-24.7%)
|
—
est: 4.71B (-100.0%)
|
4.78B
est: 5.22B (-8.3%)
|
5.32B
est: 5.94B (-10.5%)
|
3.55B
est: 6.34B (-43.9%)
|
4.00B
est: 6.91B (-42.1%)
|
4.22B
est: 7.31B (-42.3%)
|
4.58B
est: 8.10B (-43.5%)
|
4.93B
est: 9.87B (-50.1%)
|
5.45B
est: 10.18B (-46.5%)
|
5.16B
est: 10.52B (-50.9%)
|
4.84B
est: 11.29B (-57.2%)
|
4.41B
est: 11.70B (-62.3%)
|
3.05B
est: 11.70B (-73.9%)
|
2.60B
est: 12.37B (-79.0%)
|
2.64B
est: 2.85B (-7.6%)
|
2.92B
2.90B – 2.93B
+2.2% YoY
|
3.09B
3.05B – 3.14B
+6.1% YoY
|
3.21B
3.18B – 3.24B
+3.8% YoY
|
| EPS |
26.63
est.
|
24.90
est.
|
36.43
est.
|
64.48
est: 50.69 (+27.2%)
|
63.00
est: 70.37 (-10.5%)
|
73.51
est: 76.90 (-4.4%)
|
62.71
est: 71.52 (-12.3%)
|
72.16
est: 68.43 (+5.4%)
|
68.35
est: 75.63 (-9.6%)
|
100.19
est: 71.31 (+40.5%)
|
83.01
est: 85.76 (-3.2%)
|
76.71
est: 79.20 (-3.1%)
|
104.12
est: 100.06 (+4.1%)
|
85.56
est: 105.99 (-19.3%)
|
103.21
est: 75.00 (+37.6%)
|
132.09
est: 85.99 (+53.6%)
|
141.55
est: 82.62 (+71.3%)
|
165.26
est: 96.32 (+71.6%)
|
179.85
est: 120.45 (+49.3%)
|
207.38
est: 131.58 (+57.6%)
|
410.06
est: 153.88 (+166.5%)
|
269.47
est: 141.19 (+90.9%)
|
158.31
est: 143.28 (+10.5%)
|
136.21
est: 158.27 (-13.9%)
|
141.85
est: 166.03 (-14.6%)
|
168.05
163.40 – 172.70
+1.2% YoY
|
173.38
160.34 – 185.99
+3.2% YoY
|
172.50
170.39 – 174.61
-0.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-10 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-09 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-03 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-02 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.13B
OE per share TTM
92.60
Owner's Yield
2.97%
Maintenance CapEx ratio
21.44%
Maint CapEx / Avg PPE
13.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.09M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 4.05M | 0.06% |
| 3 | Vanguard ESG International Stock ETF VSGX | 0.00% | 106.3K | 0.10% |
| 4 | Vanguard Total International Stock ETF VXUS | 0.00% | 4.22M | 0.05% |
| 5 | Vanguard Total World Stock ETF VT | 0.00% | 241.6K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
4.07M
Shares Outstanding
23.03M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rachid Ayari | Chief Financial Officer & Whole Time Director | 22M | male |
| Deepak Arora | Country Lead, MD & GM of Pharma | 8M | male |
| Mahadev Gawade | Additional Whole-time Director & Site Head - Goa | 6M | male |
| K. Narayanaswamy | Senior Director of Accounting & Taxation | — | male |
| Nakul Verma | Senior Director of Public Affairs and Head of Public Affairs & Market Access | — | male |
| Nitya Padmanabhan | Head of Vaccines for Sanofi Healthcare India Private Limited | — | female |
| Richa Bakshi | Head of People Excellence | — | female |
| Sanjay V. Chavan | Head of Country Procurement - India | — | male |
| Aniket Raje | Head of Regulatory Affairs | — | male |
| Sudipta Chakraborty | Head of Legal & Whole-time Director | — | female |
| Bratin Bag | Senior Director of Ethics & Business Integrity, South Asia | — | male |
| Haresh Bachubhai Vala | Company Secretary & Compliance Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SANOFI.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
